Sanofi, AstraZeneca: FDA accepts nirsevimab application as first protective option v. RSV

 FDA accepts nirsevimab application as first protective option against RSV disease for all infants

• Nirsevimab would be the first broadly protective option against RSV disease designed for all infants, if approved
• Nirsevimab delivered consistent protection of approximately 80% against medically attended RSV disease across several trials in healthy term and preterm infants and has been approved under accelerated review in the EU and the UK

https://www.biospace.com/article/releases/press-release-fda-accepts-nirsevimab-application-as-first-protective-option-against-rsv-disease-for-all-infants/